Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3172-3184

  Ragno, Rino ^a   Coluccia, Antonio ^a   La Regina, Giuseppe ^a   De Martino, Gabriella ^a   Piscitelli, Francesco ^a   Lavecchia, Antonio ^d   Novellino, Ettore ^d   Bergamini, Alberto ^b   Ciaprini, Chiara ^b   Sinistro, Anna ^b   Maga, Giovanni ^c   Crespan, Emanuele ^c   Artico, Marino ^a   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 CHLORO 4 (2,3,4,5 TETRAHYDRO 3 OXO 6 PYRIDAZINYL)PHENOXY] N (2 MORPHOLINOETHYL)ACETAMIDE; EFAVIRENZ; INDOLE DERIVATIVE; L 737126; N (2 OXAZOLIDINON 3 YL) 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N' ISOPROPYL 3 [(3,5 DIMETHYLPHENYL)SULFONYL] 5 CHLORO 1H INDOLE 2 CARBOXYHYDRAZIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RS 1833; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; MACROPHAGE; MOLECULAR MODEL; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; CELLS, CULTURED; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; INDOLES; LYMPHOCYTES; MACROPHAGES; MODELS, MOLECULAR; PYRROLIDINONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOLUBILITY; SULFONES;

EID: 33744831188     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0512490     Document Type: Article

References (42)

1. WHO/UNAIDS, AIDS Epidemic Update, 2005.
2. Williams, I. G. Enfuvirtide (Fuzeon): The first fusion inhibitor. Int. J. Clin. Pract. 2003, 57, 890-7.
3. Vandamme, A. M.; Van Vaerenbergh, K.; De Clercq, E. Anti-human immunodeficiency virus drug combination strategies. Antivir. Chem. Chemother. 1998, 9, 187-203.
4. Tachedjian, G.; Goff Stephen, P. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr. Opin. Invest. Drugs 2003, 4, 966-73.
5. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present and future. Chem. Biodiversity 2004, 1, 44-64.
6. Artico, M.; Silvestri, R.; Pagnozzi, E.; Stefancich, G.; Massa, S.; Loi, A. G.; Putzolu, M.; Corrias, S.; Spiga, M. G.; La Colla, P. 5H-Pyrrolo[1,2-b] [1,2,5]benzothiadiazepines (PBTDs): A novel class of non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. 1996, 4, 837-50.
7. Artico, M.; Silvestri, R.; Pagnozzi, E.; Bruno, B.; Novellino, E.; Greco, G.; Massa, S.; Ettorre, A.; Loi, A. G.; Scintu, F.; La Colla, P. Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. J. Med. Chem. 2000, 45, 1886-91.
8. Artico, M.; Silvestri, R.; Massa, S.; Loi, A. G.; Corrias, S.; Piras, G.; La Colla, P. 2-Sulfonyl-4-chloroanilino moiety: A potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. J. Med. Chem. 1996, 39, 522-30.
9. Silvestri, R.; De Martino, G.; La Regina, G.; Artico, M.; Massa, S.; Vargiu, L.; Mura, M.; Loi, A. G.; Marceddu, T.; La Colla, P. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: Synthesis and SAR studies. J. Med. Chem. 2003, 46, 2482-93.
10. Silvestri, R.; Artico, M.; De Martino, G.; La Regina, G.; Loddo, R.; La Colla, M.; La Colla, P. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild-type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Med. Chem. 2004, 47, 3892-3896.
11. Silvestri, R.; Artico, M.; De Martino, G.; La Regina, G.; Loddo, R.; La Colla, M.; Mura, M.; La Colla, P. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Med. Chem. 2004, 47. 3892-6.
12. Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Rooney, C. S.; Balani, S. K.; Condra, J. H.; Emini, E. A.; Goldman, M. E.; Greenlee, W. J.; Kauffman, L. R.; et al. 5-Chloro-3-(phenylsulfonyl)-indole-2-carboxamide: A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Med. Chem. 1993, 36, 1291-4.
13. Young, S. D.; Amblard, M. C.; Brichter, S. F.; Grey, V. E.; Tran, L. O.; Lumma, W. C. J.; Huff, J. R.; Schleif, W. A.; Emini, E. E.; O'Brien, J. A.; Pettibone, D. J. 2-Heterocyclic indole-3-sulfones as Inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 1995, 5, 491-496.
14. Ragno, R.; Artico, M.; De Martino, G.; La Regina, G.; Coluccia, A.; Di Pasquali, A.; Silvestri, R. Docking and 3-D QSAR Studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-Hydroxyethyl) carboxamide and N-(2-Hydroxyethyl)-carbohydrazide derivatives. J. Med. Chem. 2005, 48, 213-223.
15. De Martino, G.; La Regina, G.; Ragno, R.; Coluccia, A.; Bergamini, A.; Ciaprini, C.; Sinistro, A.; Maga, G.; Crespan, E.; Artico, M.; Silvestri, R. Indolyl aryl sulfones (IASs). Indolyl aryl sulfones (IASs) as HIV-1 non-nucleoside reverse transcriptase inhibitors. Synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. Antiviral Chem. Chemother. 2006, in press.
16. Chan, J. H.; Hong, J. S.; Hunter, R. N. r.; Orr, G. F.; Cowan, J. R.; Sherman, D. B.; Sparks, S. M.; Reitter, B. E.; Andrews, C. W., III; Hazen, R. J.; St. Clair, M.; Boone, L. R.; Ferris, R. G.; Creech, K. L.; Roberts, G. B.; Short, S. A.; Weaver, K.; Ott, R. J.; Ren, J.; Hopkins, A.; Stuart, D. I.; Stammers, D. K. 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 2001, 44, 1866-82.
17. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. 1993, 12, 9-20.
18. Pastor, M.; Cruciani, G.; Watson, K. A. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. 1997, 40, 4089-102.
19. Silvestri, R.; Artico, M.; De Martino, G.; La Regina, G.; Loddo, R.: La Colla, M.; Mura, M.; La Colla, P. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Med. Chem. 2004, 47, 3892-6.
20. Hopkins, A. L.; Ren, J.; Milton, J.; Hazen, R. J.; Chan, J. H.; Stuart, D. I.; Stammers, D. K. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. J. Med. Chem. 2004, 47, 5912-22.
21. Silvestri, R.; De Le Martino, G.; La Regina, G.; Artico, M.; Massa, S.; Vargiu, L.; Mura, M.; Loi, A. G.; Marceddu, T.; La Colla, P. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: Synthesis and SAR studies. J. Med. Chem. 2003, 46, 2482-2493.
22. Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. Estimation of aqueous solubility of chemical compounds using E-state indices. J. Chem. Inf. Comput. Sci. 2001, 41, 1488-93.
23. Corbett, J. W.; Rodgers, J. D. Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1. Prog. Med. Chem. 2002, 40, 63-105.
24. Sodroski, J. G.; Rosen, C. A.; Haseltine, W. A. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 1984, 225, 381-5.
25. Placido, R.; Mancino, G.; Amendola, A.; Mariani, F.; Vendetti, S.; Piacentini, M.; Sanduzzi, A.; Bocchino, M. L.; Zembala, M.; Colizzi, V. Apoptosis of human monocytes/macrophages in Mycobacterium tuberculosis infection. J. Pathol. 1997, 181, 31-8.
26. Andreoni, M.; Sarmati, L.; Parisi, S. G.; Ercoli, L.; Rocchi, G. Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma. J. Med. Virol. 1992, 38, 207-13.
27. Bergamini, A.; Capozzi, M.; Ghibelli, L.; Dini, L.; Salanitro, A.; Milanese, G.; Wagner, T.; Beninati, S.; Pesce, C. D.; Amici, C.; et al. Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells. J. Clin. Invest. 1994, 93, 2251-7.
28. Karber, G. Beitrag zur kollectiven behandlung pharmakologisher reihenversuche. Arch. Exp. Pharmakol. 1931, 162, 480-483.
29. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-21.
30. Perno, C. F.; Yarchoan, R.; Cooney, D. A.; Hartman, N. R.; Gartner, S.; Popovic, M.; Hao, Z.; Gerrard, T. L.; Wilson, Y. A.; et al. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J. Exp. Med. 1988, 168, 1111-25.
31. Chou, T. C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 1976, 59, 253-76.
32. Boyer, P. L.; Tantillo, C.; Jacobo-Molina, A.; Nanni, R. G.; Ding, J.; Arnold, E.; Hughes, S. H. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4882-6.
33. Maga, G.; Amacker, M.; Ruel, N.; Hubscher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 1997, 274, 738-47.
34. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton. M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
35. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: Applications of AutoDock. J. Mol. Recog. 1996, 9, 1-5.
36. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, I. Thomas E.; DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P. AMBER, a package of computer programs for applying molecular mechanics, normal-mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Comm. 1995, 91, 1-41.
37. Berman, H.; Henrick, K.; Nakamura, H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 2003, 10, 980.
38. Ragno, R.; Marshall, G. R.; Di Santo, R.; Costi, R.; Massa, S.; Rompei, R.; Artico, M. Antimycobacterial pyrroles: Synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies. Bioorg. Med. Chem. 2000, 8, 1423-32.
39. Tafi, A.; Anastassopoulou, J.; Theophanides, T.; Botta, M.; Corelli, F.; Massa, S.; Artico, M.; Costi, R.; Di Santo, R.; Ragno, R. Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. J. Med. Chem. 1996, 59, 1227-35.
40. Ragno, R.; Frasca, S.; Manetti, F.; Brizzi, A.; Massa, S. HIV-reverse transcriptase inhibition: Inclusion of ligand-induced fit by cross-docking studies. J. Med. Chem. 2005, 48, 200-212.
41. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-57.
42. Pastor, M.; Cruciani, G.; Clementi, S. Smart region definition: A new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. J. Med. Chem. 1997, 40, 1455-64.